Latest & greatest articles for propranolol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on propranolol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on propranolol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for propranolol

1. WITHDRAWN: Propranolol for migraine prophylaxis. (Full text)

WITHDRAWN: Propranolol for migraine prophylaxis. Propranolol is one of the most commonly prescribed drugs for migraine prophylaxis.We aimed to determine whether there is evidence that propranolol is more effective than placebo and as effective as other drugs for the interval (prophylactic) treatment of patients with migraine.Potentially eligible studies were identified by searching MEDLINE/PubMed (1966 to May 2003) and the Cochrane Central Register of Controlled Trials (Issue 2, 2003 (...) ), and by screening bibliographies of reviews and identified articles.We included randomised and quasi-randomised clinical trials of at least 4 weeks duration comparing clinical effects of propranolol with placebo or another drug in adult migraine sufferers.Two reviewers extracted information on patients, methods, interventions, outcomes measured, and results using a pre-tested form. Study quality was assessed using two checklists (Jadad scale and Delphi list). Due to the heterogeneity of outcome measures

2017 Cochrane PubMed abstract

2. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. (Abstract)

A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. The objective of this article is to see whether the effect of candesartan for migraine prevention, shown in one previous study, could be confirmed in a new study, and if so, whether the effect was comparable to that of propranolol (non-inferiority analysis), and whether adverse events were different.In a randomised, triple-blind, double cross (...) -over study, 72 adult patients with episodic or chronic migraine went through three 12-week treatment periods on either candesartan 16 mg, propranolol slow-release 160 mg, or placebo. The main outcome measures were days with migraine headache per four weeks (primary outcome), days with headache, hours with headache, proportion of responders (>50% reduction of migraine days from baseline), and adverse events.In the modified intention-to treat-analysis, candesartan and propranolol were both superior

2013 Cephalalgia : an international journal of headache Controlled trial quality: predicted high

3. Propranolol

Propranolol USE OF PROPRANOLOL IN PREGNANCY 0344 892 0909 USE OF PROPRANOLOL IN PREGNANCY (Date of issue: March 2016 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Propranolol is a non-selective beta-adrenoceptor blocking drug (...) propranolol exposure and women should be made aware of this lack of data. Studies of beta-blockers as a class have not, to date, provided conclusive evidence that use during pregnancy is associated with an increased risk of fetal structural malformations. Although some studies have suggested a possible increased risk of congenital heart defects, this has also been observed with other antihypertensive therapies and may therefore be non-drug-specific or linked to the underlying maternal condition. A meta

2014 UK Teratology Information Service

4. Propranolol

Propranolol Top results for propranolol - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for propranolol The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

5. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. (Full text)

Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. To assess the efficacy and safety of adding propranolol to topiramate in chronic migraine subjects inadequately controlled with topiramate alone.This was a double-blind, placebo-controlled, randomized clinical trial conducted through the National Institute of Neurological Disorders and Stroke Clinical Research Collaboration, expected to randomize 250 chronic migraine subjects inadequately controlled (...) (≥10 headaches/month) with topiramate (50-100 mg/day) to either propranolol LA (long acting) (240 mg/day) or placebo. Primary outcome was 28-day moderate to severe headache rate reduction at 6 months (weeks 16 to 24) compared with baseline (weeks -4 to 0).A planned interim analysis was performed after 48 sites randomized 171 subjects. The data and safety monitoring board recommended ending the trial after determining that it would be highly unlikely for the combination to result in a significant

2012 Neurology Controlled trial quality: predicted high PubMed abstract

6. The Effect of Carvedilol Vs Propranolol in Cirrhotic Patients With Variceal Bleeding

The Effect of Carvedilol Vs Propranolol in Cirrhotic Patients With Variceal Bleeding The Effect of Carvedilol Vs Propranolol in Cirrhotic Patients With Variceal Bleeding - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. The Effect of Carvedilol Vs Propranolol in Cirrhotic Patients With Variceal Bleeding The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02385422 Recruitment Status : Unknown Verified March 2015 by Shiyao Chen, Shanghai Zhongshan Hospital. Recruitment status was: Recruiting First Posted

2015 Clinical Trials

7. A Comparison Between the Effect of Oxytocin Only and Oxytocin Plus Propranolol on Induction of Labor in Term Pregnancy

A Comparison Between the Effect of Oxytocin Only and Oxytocin Plus Propranolol on Induction of Labor in Term Pregnancy A Comparison Between the Effect of Oxytocin Only and Oxytocin Plus Propranolol on Induction of Labor in Term Pregnancy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. A Comparison Between the Effect of Oxytocin Only and Oxytocin Plus Propranolol on Induction of Labor in Term Pregnancy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details

2018 Clinical Trials

8. Propranolol vs Prednisolone for Symptomatic Proliferating Infantile Hemangiomas: A Randomized Clinical Trial. (Full text)

Propranolol vs Prednisolone for Symptomatic Proliferating Infantile Hemangiomas: A Randomized Clinical Trial. While propranolol is touted as superior to prednisolone for treating infantile hemangiomas (IH), a randomized clinical trial (RCT) comparing the outcome and tolerability of these medications for symptomatic, proliferating IH has not been reported.To determine if oral propranolol is more efficacious and better tolerated than prednisolone in treating symptomatic, proliferating IH (...) and to determine the feasibility of conducting a multi-institutional, RCT comparing efficacy and tolerability of both medications.Phase 2, investigator-blinded, multi-institutional RCT conducted in 3 academic vascular anomalies clinics on 19 of 44 eligible infants aged between 2 weeks and 6 months. All participating patients had symptomatic proliferating IH treated between September 1, 2010, and August 1, 2012.Treatment with oral propranolol vs prednisolone (2.0 mg/kg/d) until halted owing to toxic effects

2014 JAMA otolaryngology-- head & neck surgery Controlled trial quality: predicted high PubMed abstract

9. Randomized study comparing banding and propranolol to prevent initial variceal haemorrhage in cirrhotics with high-risk esophageal varices

Randomized study comparing banding and propranolol to prevent initial variceal haemorrhage in cirrhotics with high-risk esophageal varices Randomized study comparing banding and propranolol to prevent initial variceal haemorrhage in cirrhotics with high-risk esophageal varices Randomized study comparing banding and propranolol to prevent initial variceal haemorrhage in cirrhotics with high-risk esophageal varices Jutabha R, Jensen D M, Martin P, Savides T, Han S H, Gornbein J Record Status (...) . Of these, 197 were excluded from randomisation and 62 were randomised. Randomisation assigned 31 to prophylactic oesophageal variceal ligation and 31 to prophylactic propranolol. Study design The study was an RCT that was carried out in three centres (Los Angeles Medical Centre, San Diego Medical Centre and Veterans Administration Los Angeles HealthCare System). A separate randomisation schedule was provided for each centre in permuted blocks of 4. The follow-up period was up to 2 years. Treatment

2005 NHS Economic Evaluation Database.

10. Propranolol, post-traumatic stress disorder, and intensive care: incorporating new advances in psychiatry into the ICU (Full text)

Propranolol, post-traumatic stress disorder, and intensive care: incorporating new advances in psychiatry into the ICU Post-traumatic stress disorder (PTSD) is a common complication of an ICU admission. Rarely is there a continuation of care, which is aimed at screening for and treating this debilitating disease. Current treatment options for PTSD are held back by inconsistent efficacy, poor evidence, and a lack of understanding of its psychopathology. Without 'gold standard' assessment (...) the approach to treating PTSD. It is hoped that the phenomenon of reconsolidation can be exploited therapeutically. In the act of remembering and re-storing traumatic memories, propranolol can act to dissociate the state of sympathetic arousal from their recollection. Often, ICU patients have multiple physical co-morbidities that may be exacerbated, or their treatment disrupted, by such a pervasive psychological condition. The rapid uptake of new techniques, aimed at reducing PTSD after ICU admission

2014 Critical Care PubMed abstract

11. Comparison between combined propranolol with other therapies and propranolol monotherapy in the treatment of infantile hemangioma: a meta-analysis

Comparison between combined propranolol with other therapies and propranolol monotherapy in the treatment of infantile hemangioma: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

12. Safety of Oral Propranolol for the Treatment of Infantile Hemangioma: A Systematic Review (Full text)

Safety of Oral Propranolol for the Treatment of Infantile Hemangioma: A Systematic Review Given the widespread use of propranolol in infantile hemangioma (IH) it was considered essential to perform a systematic review of its safety. The objectives of this review were to evaluate the safety profile of oral propranolol in the treatment of IH.We searched Embase and Medline databases (2007-July 2014) and unpublished data from the manufacturer of Hemangiol/Hemangeol (marketed pediatric formulation (...) of oral propranolol; Pierre Fabre Dermatologie, Lavaur, France). Selected studies included ≥10 patients treated with oral propranolol for IH and that either reported ≥1 adverse event or effect (AE) or planned to capture AEs. Data capture was standardized and extracted study design, demographic characteristics, IH characteristics, intervention, and safety outcomes. AEs were assigned a system organ class and preferred term.A total of 83 of 398 identified literature records met the inclusion criteria

2016 EvidenceUpdates PubMed abstract

13. Preventive therapy of first gastrointestinal bleeding in patients with cirrhosis: results of a controlled trial comparing propranolol, endoscopic sclerotherapy and placebo. (Abstract)

Preventive therapy of first gastrointestinal bleeding in patients with cirrhosis: results of a controlled trial comparing propranolol, endoscopic sclerotherapy and placebo. Propranolol and endoscopic sclerosis of esophageal varices are the two approaches currently used in prophylaxis of the first gastrointestinal hemorrhage in the cirrhotic patient. One hundred twenty-six cirrhotic patients with esophageal varices and no histories of bleeding were included in the trial regardless of the gravity (...) of the cirrhosis or the size of the esophageal varices. Patients with hepatocarcinomas or other cancers, clearly impossible follow-up, previous treatment for portal hypertension or contraindication to beta-blockers were excluded. After randomization, 43 patients received propranolol twice daily at a dose reducing the heart rate by 25%; 42 patients were treated with intravariceal and extravariceal injections of Polidocanol; 41 control patients received vitamin K orally as placebo. The patients were seen at 3-mo

1990 Hepatology Controlled trial quality: uncertain

14. Comparison of propranolol and pregabalin for prophylaxis of childhood migraine: a randomised controlled trial. (Abstract)

Comparison of propranolol and pregabalin for prophylaxis of childhood migraine: a randomised controlled trial. Migraine involves 5-10% of children and adolescents. Thirty percent of children with severe migraine attacks have school absence and reduced quality of life that need preventive therapy. The purpose of this randomised control trial study is to compare the effectiveness, safety and the tolerability of pregabalin toward Propranolol in migraine prophylaxis of children. From May 2011 (...) to October 2012, 99 children 3-15 years referred to the neurology clinic of Mofid Children's Hospital with a diagnosis of migraine enrolled the study. Patients randomly divided into two groups (A&B). We treated children of group A with capsule of pregabalin as children of group B with tablet of propranolol for at least 8 weeks. In this study, 99 patients were examined that 91 children reached the last stage. The group A consistsed of 46 patients, 12(26.1%) girls, 34 (73.9%) boys and the group B consisted

2015 Acta medica Iranica Controlled trial quality: uncertain

15. Propranolol generally safe in treating childhood haemangioma birthmarks

Propranolol generally safe in treating childhood haemangioma birthmarks Propranolol generally safe in treating childhood haemangioma birthmarks Discover Portal Discover Portal Propranolol generally safe in treating childhood haemangioma birthmarks Published on 17 January 2017 doi: Treating ‘infantile haemangioma’ strawberry birthmarks with oral propranolol is known to be effective and in this review was associated with low levels of adverse events. The most common adverse events included (...) coldness in the hands and feet, diarrhoea, sleep disorders and upper respiratory infections. More serious problems such as low blood pressure, slow heart rate, over-reactivity of the airways and low blood sugar were also reported. Though rare, parents and prescribers need to be aware of these side effects. There is currently no UK guidance on treating haemangioma. The beta-blocker propranolol is usually used to treat heart conditions. Although commonly used, UK preparations of this drug

2018 NIHR Dissemination Centre

16. Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis. (Full text)

Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis. The effects of propranolol in the treatment of anxiety disorders have not been systematically evaluated previously. The aim was to conduct a systematic review and meta-analysis of randomised controlled trials, addressing the efficacy of oral propranolol versus placebo or other medication as a treatment for alleviating either state or trait anxiety in patients suffering from anxiety disorders. Eight studies (...) met the inclusion criteria. These studies concerned panic disorder with or without agoraphobia (four studies, total n = 130), specific phobia (two studies, total n = 37), social phobia (one study, n = 16), and posttraumatic stress disorder (PTSD) (one study, n = 19). Three out of four panic disorder trials qualified for pooled analyses. These meta-analyses found no statistically significant differences between the efficacy of propranolol and benzodiazepines regarding the short-term treatment

2015 Journal of psychopharmacology (Oxford, England) PubMed abstract

17. Reduction of PTSD Symptoms With Pre-Reactivation Propranolol Therapy: A Randomized Controlled Trial. (Abstract)

Reduction of PTSD Symptoms With Pre-Reactivation Propranolol Therapy: A Randomized Controlled Trial. The authors assessed the efficacy of trauma memory reactivation performed under the influence of propranolol, a noradrenergic beta-receptor blocker, as a putative reconsolidation blocker, in reducing symptoms of posttraumatic stress disorder (PTSD).This was a 6-week, double-blind, placebo-controlled, randomized clinical trial in 60 adults diagnosed with long-standing PTSD. Propranolol or placebo (...) was administered 90 minutes before a brief memory reactivation session, once a week for 6 consecutive weeks. The hypothesis predicted a significant treatment effect of trauma reactivation with propranolol compared with trauma reactivation with placebo in reducing PTSD symptoms on both the Clinician-Administered PTSD Scale (CAPS) and the patient-rated PTSD Checklist-Specific (PCL-S) in an intention-to-treat analysis.The estimated group difference in posttreatment CAPS score, adjusted for pretreatment values

2018 American Journal of Psychiatry Controlled trial quality: predicted high

18. Propranolol for the prevention of first esophageal variceal hemorrhage: a lifetime commitment? (Full text)

Propranolol for the prevention of first esophageal variceal hemorrhage: a lifetime commitment? Although beta blockers have had significant impact in the treatment of portal hypertension, the question of how long they should be continued for prevention of variceal hemorrhage remains unknown. Prospective studies on beta blockers to prevent variceal hemorrhage lack long-term follow-up, and indefinite administration of beta blockers for primary prevention of variceal bleeding has become standard (...) practice. The aim of this study was to determine the outcomes of patients in whom beta blocker therapy was discontinued. Patients completing a prospective, randomized, double-blind, placebo-controlled trial of propranolol for the primary prevention of variceal hemorrhage were tapered off of propranolol and placebo and followed prospectively for subsequent events. Of the 49 patients in the follow-up study (25 former propranolol, 24 former placebo), 9 experienced variceal hemorrhage (6 former propranolol

2001 Hepatology Controlled trial quality: predicted high PubMed abstract

19. Decreasing adrenergic or sympathetic hyperactivity after severe traumatic brain injury using propranolol and clonidine (DASH After TBI Study): study protocol for a randomized controlled trial. (Full text)

Decreasing adrenergic or sympathetic hyperactivity after severe traumatic brain injury using propranolol and clonidine (DASH After TBI Study): study protocol for a randomized controlled trial. Severe TBI, defined as a Glasgow Coma Scale ≤ 8, increases intracranial pressure and activates the sympathetic nervous system. Sympathetic hyperactivity after TBI manifests as catecholamine excess, hypertension, abnormal heart rate variability, and agitation, and is associated with poor neuropsychological (...) outcome. Propranolol and clonidine are centrally acting drugs that may decrease sympathetic outflow, brain edema, and agitation. However, there is no prospective randomized evidence available demonstrating the feasibility, outcome benefits, and safety for adrenergic blockade after TBI.The DASH after TBI study is an actively accruing, single-center, randomized, double-blinded, placebo-controlled, two-arm trial, where one group receives centrally acting sympatholytic drugs, propranolol (1 mg

2012 Trials Controlled trial quality: predicted high PubMed abstract

20. Candesartan Versus Propranolol for Migraine Prevention

Candesartan Versus Propranolol for Migraine Prevention Candesartan Versus Propranolol for Migraine Prevention - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Candesartan Versus Propranolol for Migraine (...) Information provided by (Responsible Party): Norwegian University of Science and Technology Study Details Study Description Go to Brief Summary: The main aim of the present study is to compare candesartan with propranolol for migraine prophylaxis. Condition or disease Intervention/treatment Phase Migraine Without Aura Migraine With Aura Chronic Migraine Drug: Candesartan Drug: propranolol Drug: placebo Phase 2 Phase 3 Detailed Description: Candesartan was shown to be effective for migraine prophylaxis

2009 Clinical Trials